Journals / Osteoporoz Dünyasından / 2007 / Cilt: 13 - Sayı: 3

The efficacy of nasal calcitonin on the treatment of osteoporosis in male patients with ankylosing spondylitis: A preliminary study

Ankilozan spondilitli erkek osteoporozlu hastalarda nazal kalsitonin tedavisinin etkisi: Ön çalışma

Pages
67–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As our study group was small to confirm these preliminary findings, larger studies examining the effects of different antiresorptive agents are required for determination of the appropriate treatment of osteoporosis in this chronic condition. (From the World of Osteoporosis 2007;13:67-9)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Osteoporosis is a prominent feature of advanced ankylosing spondylitis and causes decrease in bone mineral density (BMD), disturbance of bone formation and resorption and incerase in incidence of vertebral fractures.
📊
Key Findings & Data:It is believed that patients with AS have an increased susceptibility to vertebral fractures due to secondary diffuse osteoporosis.
💡
Conclusion & Impact:Conclusion: As our study group was small to confirm these preliminary findings, larger studies examining the effects of different antiresorptive agents are required for determination of the appropriate treatment of osteoporosis in this chronic condition. (From the World of Osteoporosis 2007;13:67-9)
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Kalsitonin · Erkek · Osteoporoz

Abstract

Aim: Osteoporosis is a prominent feature of advanced ankylosing spondylitis and causes decrease in bone mineral density (BMD), disturbance of bone formation and resorption and incerase in incidence of vertebral fractures. It is believed that patients with AS have an increased susceptibility to vertebral fractures due to secondary diffuse osteoporosis. The aim of this study was to evaluate the effectiveness of nasal calcitonin in male AS patients with osteoporosis. Patients and Methods: Thirty-two patients with AS were enrolled to our study. Nasal calcitonin 200 IU daily was given for one year to eleven patients with AS who had osteoporosis according to the The World Health Organization (WHO) criteria. The primary outcome measure was determined as the percentage of change in BMD o f lateral lumbar spine. Results: Although not statistically significant, at the end of calcitonin therapy for twelve months, increase in the mean lumbar spine BMD values of osteoporotic patients was observed. No new vertebral fracture was observed in one year. Calcitonin was well tolerated and no adverse event was reported. Conclusion: As our study group was small to confirm these preliminary findings, larger studies examining the effects of different antiresorptive agents are required for determination of the appropriate treatment of osteoporosis in this chronic condition. (From the World of Osteoporosis 2007;13:67-9)

Özet

Amaç: Osteoporoz, ilerlemiş Ankilozan Spondilit (AS)'in belirgin bir özelliği olup kemik mineral yoğunluğu (KMY)'nun azalmasına, kemik yapım ve yıkımının bozulmasına ve vertebra kırık insidansında artmaya neden olur. AS'li hastalarda vertebral kırık riskindeki artışın, sekonder yaygın osteoporoza bağlı olduğu düşünülmektedir. Bu çalışmanın amacı osteoporozlu erkek AS hastalarında nazal kalsitoninin etkinliğini değerlendirmekti. Hastalar ve Yöntem: Çalışmamıza AS tanılı 32 erkek hasta alındı. Dünya Sağlık Örgütü (DSÖ) kriterlerine göre osteoporozu olan AS'li 11 hastaya 1 yıl boyunca günde 200 IU nazal kalsitonin verildi. Sonuç ölçütü lateral lomber KMY'deki değişiklik yüzdesi olarak belirlendi. Bulgular: İstatistiksel olarak anlamlı olmasa da, osteoporotik hastaların 12 aylık kalsitonin tedavisi sonrası ortalama lomber KMY değerlerinde artış gözlendi. Bir yıl içinde yeni vertebral kırık gözlenmedi. Kalsitonin iyi tolere edildi ve yan etki bildirilmedi. Sonuç: Çalışma grubumuz bu öncül bulguları kanıtlamak üzere küçük olduğundan, bu kronik hastalıkta uygun osteoporoz tedavisinin belirlenmesi için değişik antirezorptif ilaçların etkilerini inceleyen büyük çalışmalara ihtiyaç bulunmaktadır. (Osteoporoz Dünyasından 2007;13:67-9

🔖

Cite This Article

BORMAN, P., BODUR, H., ESER, F., BİNGÖL, S. (2007). The efficacy of nasal calcitonin on the treatment of osteoporosis in male patients with ankylosing spondylitis: A preliminary study. Osteoporoz Dünyasından, Cilt: 13 - Sayı: 3, 67–69. https://ajindex.com/articles/286763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Van der Linden S, Ankylosing spondylitis, In: Kelley WN, Ruddy S, Harris ED, Sledge CB, editors, Textbook of Rheumatology, 5th edition, Philadelphia: WB Saunders Company 1997: 969-82
  2. MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD, Biochemical markers of bone turnover in seronegative spondyloarthropathy: relationship to disease activity, Br J Rheumatol 1997; 36: 50-3
  3. Donnely S, Doyle DV, Denton A, Rolfe I, Mc Closkey EV, Spector TD, Bone mineral density and vertebral compression fracture rates in anylosing spondylitis, Ann Rheum Dis 1994; 53: 117-21
  4. Maghraoui AE, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C, Osteoporosis, body composition, and bone turnover in ankylosing spondylitis, J Rheumatol 1999; 26: 2205-9
  5. Mitra D, Elvins DM, Collins AJ, Biochemical markers of one metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures, J Rheumatol 1999; 26: 2201-4
  6. Marhoffer W, Stracke H, Masoud H, et al, Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis, Ann Rheum Dis 1995; 54: 556-9
  7. Bronson WD, Walker SE, Hillman LS, Keisler D, Hoyt T, Allen SH, Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis, J Rheumatol 1998; 25: 929-35
  8. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D, Relationship between urinary pyridinium cross links, disease activity and disease subsets of ankylosing spondylitis, Rheumatology 1999; 38: 21-7
  9. Akıncı O, Kömürcü M, Sarısaltık H, Kocaoğlu S, Kuyurtar F, Postmenapozal Osteoporoz Tedavisinde Kalsitonin Kullanımı, Fiziksel Tıp 2000; 3: 41-6
  10. Van der Linden S, Volkenburg HA, Cats A, Evaluation of diagnostic criteria for ankylosing spondylitis, A proposal for modification of the New York Criteria, Arthritis Rheum 1984; 27: 361-8
  11. Jensen K, K, and Tougaard L, A simple x-ray method for monitoring progress of osteoporosis, Lancet 4: 19-20; 1981
  12. Bessant R, Harris C, Keat A, Audit of the diagnosis, assessment and treatment of osteoporosis in patients with ankylosing spondylitis, J Rheumatol 2003; 30: 779-82
  13. Mitra D, Elvins DM, Speden DJ, Collins AJ, The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density, Rheumatology 2000; 39: 85-89
  14. Meirelles ES, Borelli A, Camargo OP, Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss, Clin Rheumat